Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report

BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been emerged as the standard selection in non-small cell lung cancer (NSCLC) patients with EGFR sensitive mutations. However, primary or acquired resistance to EGFR-TKIs seems inevitable, especially to third-gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Junhui, Chen, Jianxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368759/
https://www.ncbi.nlm.nih.gov/pubmed/30736738
http://dx.doi.org/10.1186/s12885-019-5352-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368759/
https://www.ncbi.nlm.nih.gov/pubmed/30736738
http://dx.doi.org/10.1186/s12885-019-5352-7

Ejemplares similares